Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239
Veru Inc. (VERU) reported fiscal 2026 Q3 results ended June 30, 2026, with a net loss of $7.0 million, or $0.30 per share. The Phase 2b PLATEAU trial of enobosarm plus semaglutide is fully enrolled with 239 patients. Interim analysis is expected in Q1 2027, final topline in Q4 2027. Cash was $23.9 million.
How this was made
The 30-second read
Why it matters
The new information is the combination of (1) fiscal Q3 loss and expense trends, (2) PLATEAU fully enrolled at 239 patients, and (3) timing for interim and final topline data plus a USPTO notice of allowance for a key US patent.
Market read
Traders can reassess trial execution progress versus ongoing burn, using the updated enrollment count and the stated interim and final topline windows.
What to watch
Cash is $23.9M as of June 30, 2026, and R&D and operating losses remain substantial, which could dominate valuation even with trial progress and patent allowance.
Background
Veru is advancing a Phase 2b PLATEAU trial using enobosarm plus semaglutide for high quality weight loss, with interim analysis targeted for early calendar 2027.
Ticker impact
Veru reported fiscal Q3 net loss of $7.0M and said its PLATEAU Phase 2b trial is fully enrolled with 239 patients.
Near-term sentiment likely modestly positive on enrollment progress, offset by continued losses and limited cash runway.
The article provides concrete trial status (fully enrolled) and a timeline for interim and final topline data, but it does not include revenue upside or a balance-sheet improvement beyond the stated cash figure.
Market effects
Adds another datapoint for obesity/weight-loss drug development timelines and the competitive importance of trial enrollment and IP protection.
No clear regional spillover beyond US biotech sentiment.
Novo Nordisk supply agreement mention may reinforce global supply-chain and collaboration expectations in GLP-1-adjacent development.
Counterpoint
Fully enrolled does not guarantee efficacy; interim results being “on track” is not the same as positive clinical signals, so the stock may still trade primarily on cash burn and future topline risk.
Key entities
- companyVeru Inc.
Reported fiscal 2026 Q3 net loss and provided an update that PLATEAU is fully enrolled with 239 patients, with interim analysis on track for Q1 2027.
- clinical_trialPLATEAU
Phase 2b trial of enobosarm and semaglutide for high quality weight loss; enrollment completed at 239 patients.
- partnerNovo Nordisk
Cited a June 2026 clinical supply agreement related to the trial.
- regulatorUSPTO
Issued an August 2026 notice of allowance for a key US patent expected to protect until at least October 2044.
